264 related articles for article (PubMed ID: 15149738)
21. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
[TBL] [Abstract][Full Text] [Related]
22. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice.
Raina K; Singh RP; Agarwal R; Agarwal C
Cancer Res; 2007 Jun; 67(12):5976-82. PubMed ID: 17575168
[TBL] [Abstract][Full Text] [Related]
23. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
24. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
25. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.
Bethel CR; Bieberich CJ
Prostate; 2007 Dec; 67(16):1740-50. PubMed ID: 17929276
[TBL] [Abstract][Full Text] [Related]
26. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.
Caporali A; Davalli P; Astancolle S; D'Arca D; Brausi M; Bettuzzi S; Corti A
Carcinogenesis; 2004 Nov; 25(11):2217-24. PubMed ID: 15358631
[TBL] [Abstract][Full Text] [Related]
27. Dynamic profiling of estrogen receptor and epidermal growth factor signaling in the uteri of genistein- and estrogen-treated rats.
Cotroneo MS; Fritz WA; Lamartiniere CA
Food Chem Toxicol; 2005 May; 43(5):637-45. PubMed ID: 15778002
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors.
Plymate SR; Tennant MK; Culp SH; Woodke L; Marcelli M; Colman I; Nelson PS; Carroll JM; Roberts CT; Ware JL
Prostate; 2004 Nov; 61(3):276-90. PubMed ID: 15368471
[TBL] [Abstract][Full Text] [Related]
29. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
[TBL] [Abstract][Full Text] [Related]
30. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
33. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
34. Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and down-regulation of androgen receptor.
Oh HY; Leem J; Yoon SJ; Yoon S; Hong SJ
Biochem Biophys Res Commun; 2010 Mar; 393(2):319-24. PubMed ID: 20138837
[TBL] [Abstract][Full Text] [Related]
35. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
Raghow S; Hooshdaran MZ; Katiyar S; Steiner MS
Cancer Res; 2002 Mar; 62(5):1370-6. PubMed ID: 11888907
[TBL] [Abstract][Full Text] [Related]
36. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer.
Leman ES; Madigan MC; Brünagel G; Takaha N; Coffey DS; Getzenberg RH
J Cell Biochem; 2003 Feb; 88(3):599-608. PubMed ID: 12532335
[TBL] [Abstract][Full Text] [Related]
37. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
[TBL] [Abstract][Full Text] [Related]
38. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6.
Garcia GE; Wisniewski HG; Lucia MS; Arevalo N; Slaga TJ; Kraft SL; Strange R; Kumar AP
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):980-8. PubMed ID: 16467113
[TBL] [Abstract][Full Text] [Related]
39. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
40. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
